{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T03:40:57Z","timestamp":1792726857538,"version":"4.5.0"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":30,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010663","name":"H2020 European Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001826","name":"Netherlands Organisation for Health Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1053\/j.seminhematol.2026.09.006","type":"journal-article","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T23:41:25Z","timestamp":1790811685000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["From ribosomal stress to clonal adaptation: Del(5q) MDS as a paradigmatic acquired ribosomopathy"],"prefix":"10.1053","author":[{"given":"Juliette E.","family":"Pearce","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephani","family":"Schmitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0749-1565","authenticated-orcid":false,"given":"Rebekka K.","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"16","key":"10.1053\/j.seminhematol.2026.09.006_bib0001","doi-asserted-by":"crossref","first-page":"3196","DOI":"10.1182\/blood-2009-10-178129","article-title":"Ribosomopathies: human disorders of ribosome dysfunction","volume":"115","author":"Narla","year":"2010","journal-title":"Blood"},{"issue":"9","key":"10.1053\/j.seminhematol.2026.09.006_bib0002","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1242\/dmm.020529","article-title":"Ribosomopathies: how a common root can cause a tree of pathologies","volume":"8","author":"Danilova","year":"2015","journal-title":"Dis Model Mech"},{"issue":"6363","key":"10.1053\/j.seminhematol.2026.09.006_bib0003","doi-asserted-by":"crossref","DOI":"10.1126\/science.aan2755","article-title":"Ribosomopathies: there\u2019s strength in numbers","volume":"358","author":"Mills","year":"2017","journal-title":"Science"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.09.006_bib0004","article-title":"Ribosomal proteins and human diseases: molecular mechanisms and targeted therapy","volume":"6","author":"Kang","year":"2021","journal-title":"Signal Transduct Target Ther"},{"issue":"7","key":"10.1053\/j.seminhematol.2026.09.006_bib0005","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/nm.3557","article-title":"Altered translation of GATA1 in Diamond-Blackfan anemia","volume":"20","author":"Ludwig","year":"2014","journal-title":"Nat Med"},{"issue":"3","key":"10.1053\/j.seminhematol.2026.09.006_bib0006","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/nm.4047","article-title":"Rps14 haploinsufficiency causes a block in erythroid differentiation mediated by S100A8 and S100A9","volume":"22","author":"Schneider","year":"2016","journal-title":"Nat Med"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.09.006_bib0007","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/bjh.18163","article-title":"Evolution of severe (transfusion-dependent) anaemia in myelodysplastic syndromes with 5q deletion is characterized by a macrophage-associated failure of the eythropoietic niche","volume":"198","author":"Buesche","year":"2022","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1053\/j.seminhematol.2026.09.006_bib0008","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1182\/blood.2019000947","article-title":"Diamond-Blackfan anemia","volume":"136","author":"Da Costa","year":"2020","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.09.006_bib0009","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-21588-4","article-title":"Distinct genetic pathways define pre-malignant versus compensatory clonal hematopoiesis in Shwachman-Diamond syndrome","volume":"12","author":"Kennedy","year":"2021","journal-title":"Nat Commun"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.09.006_bib0010","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-023-40896-5","article-title":"Convergent somatic evolution commences in utero in a germline ribosomopathy","volume":"14","author":"Machado","year":"2023","journal-title":"Nat Commun"},{"issue":"13","key":"10.1053\/j.seminhematol.2026.09.006_bib0011","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1182\/blood.2022017739","article-title":"Predisposition to myeloid malignancies in Shwachman-Diamond syndrome: biological insights and clinical advances","volume":"141","author":"Reilly","year":"2023","journal-title":"Blood"},{"issue":"13","key":"10.1053\/j.seminhematol.2026.09.006_bib0012","doi-asserted-by":"crossref","first-page":"4385","DOI":"10.1182\/blood-2007-03-082404","article-title":"New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients","volume":"110","author":"Haase","year":"2007","journal-title":"Blood"},{"issue":"5","key":"10.1053\/j.seminhematol.2026.09.006_bib0013","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1053\/j.seminoncol.2011.04.010","article-title":"Molecular dissection of the 5q deletion in myelodysplastic syndrome","volume":"38","author":"Ebert","year":"2011","journal-title":"Semin Oncol"},{"issue":"26","key":"10.1053\/j.seminhematol.2026.09.006_bib0014","doi-asserted-by":"crossref","first-page":"5803","DOI":"10.1182\/blood-2010-04-273771","article-title":"Advances in the 5q\u2212 syndrome","volume":"116","author":"Boultwood","year":"2010","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.09.006_bib0015","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/sj.leu.2403189","article-title":"Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del(5q) including band q31","volume":"18","author":"Giagounidis","year":"2003","journal-title":"Leukemia"},{"issue":"5","key":"10.1053\/j.seminhematol.2026.09.006_bib0016","doi-asserted-by":"crossref","first-page":"784","DOI":"10.3324\/haematol.2010.038620","article-title":"NPM1 gene deletions in myelodysplastic syndromes with 5q- and complex karyotype","volume":"96","author":"Ammatuna","year":"2011","journal-title":"Haematologica"},{"issue":"9","key":"10.1053\/j.seminhematol.2026.09.006_bib0017","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0012855","article-title":"NPM1 deletion is associated with gross chromosomal rearrangements in leukemia","volume":"5","author":"La Starza","year":"2010","journal-title":"PLoS One"},{"issue":"7176","key":"10.1053\/j.seminhematol.2026.09.006_bib0018","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nature06494","article-title":"Identification of RPS14 as a 5q- syndrome gene by RNA interference screen","volume":"451","author":"Ebert","year":"2008","journal-title":"Nature"},{"issue":"3","key":"10.1053\/j.seminhematol.2026.09.006_bib0019","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/ejh.13207","article-title":"Molecular pathogenesis of myelodysplastic syndromes with deletion 5q","volume":"102","author":"Lee","year":"2019","journal-title":"Eur J Haematol"},{"issue":"3","key":"10.1053\/j.seminhematol.2026.09.006_bib0020","doi-asserted-by":"crossref","first-page":"746","DOI":"10.3324\/haematol.2019.239970","article-title":"Integrated analyses of translatome and proteome identify the rules of translation selectivity in RPS14-deficient cells","volume":"106","author":"Boussaid","year":"2020","journal-title":"Haematologica"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.09.006_bib0021","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a007898","article-title":"The b-catenin destruction complex","volume":"5","author":"Stamos","year":"2012","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"4","key":"10.1053\/j.seminhematol.2026.09.006_bib0022","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ccr.2014.08.001","article-title":"Role of casein kinase 1A1 in the biology and targeted therapy of del(5q) MDS","volume":"26","author":"Schneider","year":"2014","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.09.006_bib0023","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-21588-4","article-title":"Distinct genetic pathways define pre-malignant versus compensatory clonal hematopoiesis in Shwachman-Diamond syndrome","volume":"12","author":"Kennedy","year":"2021","journal-title":"Nat Commun"},{"issue":"15","key":"10.1053\/j.seminhematol.2026.09.006_bib0024","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1200\/JCO.2010.31.8576","article-title":"TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression","volume":"29","author":"J\u00e4dersten","year":"2011","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1053\/j.seminhematol.2026.09.006_bib0025","doi-asserted-by":"crossref","first-page":"498","DOI":"10.3324\/haematol.2016.152025","article-title":"Progression in patients with low- and intermediate-1-risk del(5q) myelodysplastic syndromes is predicted by a limited subset of mutations","volume":"102","author":"Scharenberg","year":"2016","journal-title":"Haematologica"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2026.09.006_bib0026","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1182\/blood-2021-151926","article-title":"Deficiency of RPS14 beyond the haploinsufficient loss in del(5q)","volume":"138","author":"Adema","year":"2021","journal-title":"Blood"},{"issue":"2","key":"10.1053\/j.seminhematol.2026.09.006_bib0027","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/bjh.13563","article-title":"CSNK1A1 mutations and gene expression analysis in myelodysplastic syndromes with del(5q)","volume":"171","author":"Bello","year":"2015","journal-title":"Br J Haematol"},{"issue":"9","key":"10.1053\/j.seminhematol.2026.09.006_bib0028","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1038\/leu.2015.49","article-title":"Frequency and prognostic impact of casein kinase 1A1 mutations in MDS patients with deletion of chromosome 5q","volume":"29","author":"Heuser","year":"2015","journal-title":"Leukemia"},{"issue":"5","key":"10.1053\/j.seminhematol.2026.09.006_bib0029","doi-asserted-by":"crossref","first-page":"e212","DOI":"10.1016\/S2352-3026(15)00050-2","article-title":"CSNK1A1 mutations and isolated del(5q) abnormality in myelodysplastic syndrome: a retrospective mutational analysis","volume":"2","author":"Smith","year":"2015","journal-title":"Lancet Haematol"},{"key":"10.1053\/j.seminhematol.2026.09.006_bib0030","doi-asserted-by":"crossref","DOI":"10.1038\/s41375-026-03122-x","article-title":"Csnk1a1 E98 mutations rewire signaling and metabolism in del(5q) myelodysplastic neoplasms","author":"Schmitz","year":"2026","journal-title":"Leukemia"},{"issue":"7","key":"10.1053\/j.seminhematol.2026.09.006_bib0031","doi-asserted-by":"crossref","first-page":"3859","DOI":"10.1182\/blood-2007-06-098251","article-title":"Npm1 is a haploinsufficient suppressor of myeloid and lymphoid malignancies in the mouse","volume":"111","author":"Sportoletti","year":"2008","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2026.09.006_bib0032","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2011\/195209","article-title":"NPM1\/B23: a multifunctional chaperone in ribosome biogenesis and chromatin remodeling","volume":"2011","author":"Lindstr\u00f6m","year":"2011","journal-title":"Bioche Res Int"},{"issue":"12","key":"10.1053\/j.seminhematol.2026.09.006_bib0033","article-title":"Nucleophosmin, a multifunctional nucleolar organizer with a role in DNA repair","volume":"1868","author":"L\u00f3pez","year":"2020","journal-title":"Biochim Biophys Acta (BBA)"},{"issue":"2","key":"10.1053\/j.seminhematol.2026.09.006_bib0034","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/s41375-024-02476-4","article-title":"Functions of the native NPM1 protein and its leukemic mutant","volume":"39","author":"Falini","year":"2024","journal-title":"Leukemia"},{"issue":"10","key":"10.1053\/j.seminhematol.2026.09.006_bib0035","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1182\/blood.2024026113","article-title":"Posttranscriptional depletion of ribosome biogenesis factors engenders therapeutic vulnerabilities in NPM1-mutant AML","volume":"146","author":"Damaskou","year":"2025","journal-title":"Blood"},{"issue":"10","key":"10.1053\/j.seminhematol.2026.09.006_bib0036","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1038\/s41375-022-01666-2","article-title":"Current status and future perspectives in targeted therapy of NPM1-mutated AML","volume":"36","author":"Ranieri","year":"2022","journal-title":"Leukemia"},{"issue":"12","key":"10.1053\/j.seminhematol.2026.09.006_bib0037","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1200\/JCO.2011.36.1824","article-title":"Topography, clinical, and genomic correlates of 5q myeloid malignancies revisited","volume":"30","author":"Jerez","year":"2012","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1053\/j.seminhematol.2026.09.006_bib0038","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.pathol.2020.03.010","article-title":"The effect of miR-223 on cellular behaviour in non-5q myelodysplastic syndromes through targeting RPS14","volume":"52","author":"Nie","year":"2020","journal-title":"Pathology"},{"issue":"4","key":"10.1053\/j.seminhematol.2026.09.006_bib0039","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1179\/1607845413Y.0000000127","article-title":"Ribosomal protein S14 silencing inhibits growth of acute myeloid leukemia transformed from myelodysplastic syndromes via activating p53","volume":"19","author":"Wang","year":"2013","journal-title":"Hematology"},{"issue":"7559","key":"10.1053\/j.seminhematol.2026.09.006_bib0040","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/nature14610","article-title":"Lenalidomide induces ubiquitination and degradation of CK1\u03b1 in del(5q) MDS","volume":"523","author":"Kr\u00f6nke","year":"2015","journal-title":"Nature"},{"issue":"2","key":"10.1053\/j.seminhematol.2026.09.006_bib0041","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1177\/2040620711435659","article-title":"Efficacy and safety of lenalidomide in patients with myelodysplastic syndrome with chromosome 5q deletion","volume":"3","author":"Duong","year":"2012","journal-title":"Ther Adv Hematol"},{"issue":"5","key":"10.1053\/j.seminhematol.2026.09.006_bib0042","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1158\/1078-0432.CCR-21-1295","article-title":"Results from a first-in-human phase I study of Siremadlin (HDM201) in patients with advanced wild-type TP53 solid tumors and acute leukemia","volume":"28","author":"Stein","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.09.006_bib0043","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-023-00871-1","article-title":"A Phase I study of Milademetan (DS3032b) in combination with low dose cytarabine with or without venetoclax in acute myeloid leukemia: clinical safety, efficacy, and correlative analysis","volume":"13","author":"Senapati","year":"2023","journal-title":"Blood Cancer J"},{"key":"10.1053\/j.seminhematol.2026.09.006_bib0044","doi-asserted-by":"crossref","first-page":"2903","DOI":"10.2147\/OTT.S172315","article-title":"MDM2 antagonists as a novel treatment option for acute myeloid leukemia: perspectives on the therapeutic potential of idasanutlin (RG7388)","volume":"12","author":"Khurana","year":"2019","journal-title":"OncoTargets Ther"},{"issue":"9","key":"10.1053\/j.seminhematol.2026.09.006_bib0045","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1038\/s41375-021-01192-7","article-title":"Dactinomycin induces complete remission associated with nucleolar stress response in relapsed\/refractory NPM1-mutated AML","volume":"35","author":"Gionfriddo","year":"2021","journal-title":"Leukemia"},{"issue":"12","key":"10.1053\/j.seminhematol.2026.09.006_bib0046","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.3324\/haematol.2016.158857","article-title":"Pro-inflammatory proteins S100A9 and tumor necrosis factor-\u03b1 suppress erythropoietin elaboration in myelodysplastic syndromes","volume":"102","author":"Cluzeau","year":"2017","journal-title":"Haematologica"},{"issue":"11","key":"10.1053\/j.seminhematol.2026.09.006_bib0047","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1182\/blood-2011-10-382986","article-title":"L-Leucine improves the anemia and developmental defects associated with Diamond-Blackfan anemia and del(5q) MDS by activating the mTOR pathway","volume":"120","author":"Payne","year":"2012","journal-title":"Blood"},{"issue":"5","key":"10.1053\/j.seminhematol.2026.09.006_bib0048","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.exphem.2013.12.010","article-title":"Translation of branched-chain aminotransferase-1 transcripts is impaired in cells haploinsufficient for ribosomal protein genes","volume":"42","author":"Pereboom","year":"2014","journal-title":"Exp Hematol"},{"issue":"14","key":"10.1053\/j.seminhematol.2026.09.006_bib0049","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJMoa061292","article-title":"Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion","volume":"355","author":"List","year":"2006","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1053\/j.seminhematol.2026.09.006_bib0050","doi-asserted-by":"crossref","first-page":"3765","DOI":"10.1182\/blood-2011-01-330126","article-title":"A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with low-\/intermediate-1-risk myelodysplastic syndromes with del5q","volume":"118","author":"Fenaux","year":"2011","journal-title":"Blood"},{"issue":"6","key":"10.1053\/j.seminhematol.2026.09.006_bib0051","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.3324\/haematol.2013.098103","article-title":"p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q)","volume":"99","author":"Saft","year":"2014","journal-title":"Haematologica"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S003719632600096X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S003719632600096X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T03:27:19Z","timestamp":1792726039000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S003719632600096X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":51,"alternative-id":["S003719632600096X"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2026.09.006","relation":{},"ISSN":["0037-1963"],"issn-type":[{"value":"0037-1963","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"From ribosomal stress to clonal adaptation: Del(5q) MDS as a paradigmatic acquired ribosomopathy","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2026.09.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}